Analyst Insight: In 2015, I predicted that the healthcare industry was finally sharpening its focus on profitability and efficiency. While I was writing this Walgreens moved on Rite-Aid and further consolidated the retail pharmacy market, but more importantly strengthened their negotiating leverage on price breaks. If the cost of the supply chain from sourcing to production to distribution was not a priority, it just became critical to profit margins and customer service. - Brian Hudock, Partner, Tompkins International

Analyst Insight: The pharmaceutical industry is finally sharpening its focus on profitability and efficiency. 2014 saw continued mergers and acquisitions, but more importantly, the acceleration of business focus on core sectors. Now that the impacts of the Affordable Care Act are better understood, the ability to streamline operations into sectors is driving spin-offs, sell-offs and renewed operational pressures. Two key drivers this year involving supply chains will be inventory reduction and control and lean cost reduction. – Brian Hudock, Partner, Tompkins International

Analyst Insight: If 2012 was the year of climbing the emerging market mountain, then 2013 was the cliff. Not just for patents, but also in succeeding across multiple global markets. Quality issues, bad business practices, failure to integrate acquisitions, these were all common threads. Reputable players stumbled. Lesson learned: focusing on core business is the key to success. Many smaller non-core acquisitions such as animal health, devices, and OTC products will continue to spin off. Emerging and core markets will focus on profitability and smart growth, not just volume. - Brian Hudock, Partner, Tompkins International